Paula Antonia Mauloni, Federica Capuani, Clara Paone, Giovanni Marasco, Lara Bellacosa, Rosanna Francesca Cogliandro, Cesare Cremon, Giovanni Barbara, Francesco Vasuri, Vincenzo Stanghellini
Olmesartan is an angiotensin II receptor blocker, approved in 2002 by the Food and Drug Administration for the treatment of hypertension. During chronic therapy with olmesartan, sprue-like enteropathy can occur, being mainly characterised by non-bloody diarrhoea, weight loss and variable degrees of duodenal mucosal damage, which resolved after withdrawal of olmesartan. We hereby report the case of a 77-year-old, poli-treated male patient with a 3-month history of diarrhoea, vomiting and weight loss, associated with severe intestinal villous atrophy and lymphocytic infiltration of gastric and colonic mucosa...
December 1, 2021: European Journal of Gastroenterology & Hepatology